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It is essential that we develop a better understanding of how 
radiation interacts with cells at the cellular and molecular 
level, both to understand the nature of radiation-induced 
cancers resulting from radio-therapy and to devise more 
effective treatments, especially combining radiation therapy 
with other treatment modalities. Key to this is a more 
complete understanding of the underpinning radiobiology. 
OPEN-MED would aim to provide a coherent homogeneous 
database which is now necessary to take advantage of the 
recent rapid advances in cellular and molecular biology, 
using a wide range of human derived cells and eventually 
tissues. This requires advanced computational infrastructure 
which is also available at CERN.  
Therefore it is proposed to convert the existing accelerator 
LEIR at CERN, which is used typically for a few months each 
year for pre-accelerating heavy ions (mostly lead) for the 
Large Hadron Collider, by adding a new set of ion sources 
(protons, light ions such as lithium, boron and carbon and 
perhaps heavier ions like oxygen and neon), a new extracted 
beam line and a radiobiology facility dedicated to 
radiobiology experiments for at least eight months of each 
year. 
Unique features of the facility would be:   
• A range of ions  from proton to oxygen at the first  
stage, but using higher energies and other ions   
relevant  for  space  radiobiology  in a later second 
phase 
• Versatile energy, charge, mass, beam switching and 
pulsed capabilities 
• Versatile biological end station for optimal sample 
configuration and analysis 
• Beam time availability for 8 months each year 
• Internationally shared expertise 
 
The facility would enhance research training standards with 
benefits to medical physics, radiation biology, radiation 
oncology and radioprotection. The data acquired would lead 
to an improved understanding of the technical requirements 
for the design of future accelerators and associated 
technology for cancer therapy. This strategy would provide 
the capability for a systematic assay of radiobiological 
properties, and be complementary to the clinical research in 
hospitals and other places, where in vivo and specific trials 
translating this work into clinical use can be performed. 
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Purpose: To present novel modeling results showing the 
feasibility of proton pencil beam scanning (PBS) in the 
presence of an MRI scanner. This is a key requirement of 
potential future MRI Guide Proton Therapy systems [1].  
Materials and Methods: Magnetic and Monte Carlo modelling 
of a 1 T split-bore MRI system[2] coupled with a proton pencil 
beam scanning assembly (Universal Head, IBA, Belgium) were 
performed (figure 1a). The impact of an active scanning PBS 
assembly on the MRI imaging potential was assessed as well 
as the impact of the MRI fringe field on performance of the 
PBS system. 
Results: With the PBS assembly present the MR imaging field 
non-uniformity increased from 7 parts per million (ppm) to 55 
ppm which is correctable via conventional shimming. With 
full scanning currents (active mode) the non-uniformity was 
55+/-2.5 ppm. Thus MR image quality is expected to be 
maintained with dynamic scanning. Monte Carlo modelling 
further predicts that the MRI fringe field does not perturb the 
inherent magnetic deflection process of the PBS assembly. 
However once scanned, the pencil beams undergo an energy 
dependent and complex 3D deflection as they pass through 
the MRI fringe field[1]. Therefore a detailed calibration 
process is required to correct for each pencil beam so that 
PBS can be performed accurately. This correction process will 
be integrated in the plan optimization process to account for 
the magnetic field within a patient[3,4]. As an example, the 
path of a 170 MeV pencil beam is shown in a water phantom, 
and then what is required to obtain the same Bragg-peak 
with the fringe field (figure 1b and 1c). Both energy and 
direction changes are required. 
 
Figure1. (a) Layout of the MRI Guided Proton Therapy system 
showing the MRI scanner, patient location, and PBS assembly.  
(b) Path of a 170 MeV proton pencil beam (blue) with no MRI 
fringe field entering a water phantom.  (c) Path of a steered 
173 MeV pencil beam passing through the fringe field. Both of 
these beams have a Bragg-peak at 190 mm depth on the 
beam central axis. Secondary electrons are shown in red. 
 
Conclusions: PBS in MRI-guided proton therapy appears 
feasible with current methods. Calibration of the inherent 
fringe field deflections of proton beams will be an essential 
part of the commissioning process. Future work will include 
modeling of the expected performance of beam monitoring 
devices in the presence of MRI fringe fields. 
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Purpose: We undertake a preliminary Monte Carlo study to 
assess the suitability (in terms of radiation dose response) of 
a novel monolithic silicon detectoras a possible array 
detector for use in MRI-linac facilities.  
Methods: The detector, named MagicPlate512 (M512), is a 
thin (470 μm) monolithic silicon with 512 diodes spaced 2 mm 
apart across a maximum detection area of 46 x 46 mm2. The 
array has been designed specifically for small-field 
measurements [1]. Using the GEANT4 toolkit (v9.6.p02), the 
M512’s geometry was simulated at 1.5 cm depth in a 30 x 30 
x 30 cm3 water phantom at 100 cm SSD. Phase space files 
based on the spectrum of a 6MV linac [2] were used as the 
particle source. Field sizes ranging from 0.5 x 0.5 cm2 to 3 x 
3 cm2 were used. Uniform magnetic fields of strength 1 T and 
3 T were applied, in both the in-line and perpendicular 
magnetic-field-to-photon-beam orientations. Simulations 
were run until the average of 100 runs gave 0.5% error along 
the central axis, which generally involved recycling particles 
780 times (approx. 96 CPUh).  
Results: In the in-line orientation, the M512 responds to 
within 3% of the water equivalent response, which is 
comparable to the zero-field case (see Figure 1 parts (a) and 
(b)). In the perpendicular orientation we see an over- and 
under- response in opposing penumbral regions respectively 
(along the Lorentz force vector running from left to right, see 
Figure 1 part (c)). The behavior in penumbral regions is 
similar to that of the silicon array detector previously 
investigated [3] by this group. 
We also observed the consequences of a 2 mm air gap above 
the detector’s sensitive volumes for the perpendicular field 
orientation; it caused a drop in output of (22.0 ± 0.5)% and 
(57.0 ± 0.5)% for 1 T and 3 T field strengths respectively, 
relative to the 0 T case. 
 
 
 
Figure 1: Dose-difference maps of the M512 compared to the 
water-equivalent case, for zero magnetic field (part (a)), a 3 
T in-line magnetic field (part (b)) and a 3 T perpendicular 
magnetic field (part (c)). The dotted line represents the 
photon field edge (1 x 1 cm2). Adjacent pixels are spaced 2 
mm apart. 
 
Conclusions: The M512 is expected to be a valuable tool for 
2D dose-mapping in MRI-linac facilities, especially considering 
its closely pitched diodes for detecting changes to beam 
profiles in a magnetic field. Future work includes 
experimental validation of simulation results using a custom 
designed permanent magnet system. 
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Purpose: Recent advances of immunotherapy make possible 
to combine with radiotherapy. Applying a radiobiological 
model for radiotherapy is one of the methods to optimize 
treatment plans and regimens, biologically. The aim of this 
study was to assess the NTCP model with immunological 
aspects1,2) including stochastic distribution as intercellular 
uncertainties.  
Material/Methods: In the clinical 3D radiotherapy treatment 
planning system (Eclipse ver.11.0, Varian medical systems, 
US), biological parameters3) such as α/β, n, m, TD50 including 
repair parameters (repair half-life) can be set as any given 
values to calculate the NTCP of normal tissues such as the 
rectum and bladder. Using a prostate cancer patient data 
with VMAT commissioned as a 6 MV photon beam of Novalis-
Tx (BrainLab, US) in clinical use, the dose fraction protocols 
in this analysis were set as 70-78Gy/35-39fr, 72-81Gy/40-
45fr, 52.5-66Gy/16-22fr, 35-40Gy/5fr of 5-7 fractions in a 
week. By use of stochastic biological model applying for 
Gaussian distribution, the effects of the NTCP variation of 
repair parameters of the immune system as well as the 
intercellular uncertainty of normal tissues have been 
evaluated. 
Results: As respect to the difference of the α/β, the changes 
of the NTCP between fraction schedules were increased 
especially in hypo-fraction regimens. The difference of the n, 
m affects the variation of the NTCP with the fraction 
schedules, independently.  The elongation of repair half-time 
(long) increased the NTCP twice or much higher in case of 
hypo-fraction scheme. The effects of stochastic distributions 
of the α/β affects the increase of the NTCP, however the 
distributions of the m affects decrease of the NTCP in case of 
hypo-fraction schemes. 
Conclusion: We have shown the variety and difference of the 
α/β, n, m, TD50 including repair parameters (repair half-life) 
of normal tissues compared to default fixed value, which 
have highly affected by probability of cell death and cure. 
Hypo-fractionation schemes seemed to have advantages for 
the variations of the m, while disadvantages for the 
variations of the α/β. The possibility of an increase of the 
